Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study

Lancet

Volumn 357, Issue 9268, 2001, Pages 1576-1582

  Comi, Giancarlo ^a   Filippi, Massimo ^a   Barkhof, Frederik ^b   Durelli, Luca ^c   Edan, Gilles ^d   Fernández, Oscar ^e   Hartung, Hans Peter ^f   Seeldrayers, Pierrette ^g   Sørensen, Per Soelberg ^h   Rovaris, Marco ^a   Martinelli, Vittorio ^a   Hommes, Otto R ⁱ  

^a Department of Cardiology   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITÉ DE RENNES 1   (France)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f UNIVERSITY OF GRAZ   (Austria)

^g Centre Hospitalier Universitaire de Charleroi   (Belgium)

^h Rigshospitalet   (Denmark)

ⁱ European Charcot Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FEVER; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE;

EID: 0035912520     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04725-5     Document Type: Article

References (32)

1. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 103:1980;281-300.
2. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of multiple sclerosis: a geographically based study-1, clinical course and disability. Brain. 112:1989;133-146.
3. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain. 120:1997;393-399.
4. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 338:1998;278-285.
5. Fu L., Matthews P.M., De Stefano N., et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 121:1998;103-113.
6. Iannucci G., Tortorella C., Rovaris M., Sormani M.P., Comi G., Filippi M. The prognostic value of MR and MTI findings at presentation in patients with clinically isolated syndromes suggestive of MS. Am J Neuroradiol. 21:2000;1034-1038.
7. Filippi M., Horsfield M.A., Morrissey S.P., et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 44:1994;635-641.
8. O'Riordan J.I., Thompson A.J., Kingsley D.P.E., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain. 121:1998;495-503.
9. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 120:1997;2059-2069.
10. Brex P.A., Jenkins R., Fox N.C., et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology. 54:2000;1689-1691.
11. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I, clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
12. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 39:1996;285-294.
13. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
14. Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon b-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679-86.
15. Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 51:1998;682-689.
16. Beck R.W., Cleary P.A., Anderson M.M. Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis Study Group. N Engl J Med. 326:1992;581-588.
17. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 1997; 49: 1404-13.
18. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
19. Sipe J.C., Knobler R.L., Braheny S., et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology. 34:1984;1368-1372.
20. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
21. Miller D.H., Barkhof F., Berry I., Kappos L., Scotti G., Thompson A.J. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry. 54:1991;683-688.
22. Barkhof F., Filippi M., van Waesberghe J.H., et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 49:1997;1682-1688.
23. Rovaris M., Filippi M., Calori G., et al. Intra-observer reproducibility in measuring new MR putative markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol. 244:1997;266-270.
24. Martinelli V., Comi G., Filippi M., et al. Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up. Acta Neurol Scand. 84:1991;231-236.
25. Calabresi P., Stone L.A., Bash C.N., Frank J.A., McFarland H.F. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology. 48:1997;1446-1448.
26. Davie C.A., Silver N.C., Barker G.J., et al. Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry. 67:1999;710-715.
27. Trapp B.D., Ransohoff R., Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol. 12:1999;295-302.
28. Comi G. Why treat early multiple sclerosis patients? Curr Opin Neurol. 13:2000;235-240.
29. European Study Group on Interferon b-1b in secondary progressive multiple sclerosis. Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive MS. Lancet 1998; 352: 1491-97.
30. Goodkin DE and The North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54: 2352 (abstr).
31. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a (Serono) in MS (SPECRTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology (in press).
32. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 343:2000;898-904.